Blood markers could predict which lung cancer patients will resist top drug

Researchers have identified immune factors in blood plasma that signal whether advanced lung cancer patients will stop responding to osimertinib, a leading targeted therapy. The discovery could help oncologists switch treatments earlier, potentially improving survival—and reducing wasted spending on ineffective drugs.

Originaltitel: Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients